z-logo
Premium
A novel IL‐1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types.
Author(s) -
McMahan C.J.,
Slack J.L.,
Mosley B.,
Cosman D.,
Lupton S.D.,
Brunton L.L.,
Grubin C.E.,
Wignall J.M.,
Jenkins N.A.,
Brannan C.I.
Publication year - 1991
Publication title -
the embo journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.484
H-Index - 392
eISSN - 1460-2075
pISSN - 0261-4189
DOI - 10.1002/j.1460-2075.1991.tb07831.x
Subject(s) - corporation , biology , cell and molecular biology , library science , experimental biology , computational biology , genetics , gene , computer science , political science , plant development , law
cDNA clones corresponding to an Mr approximately 80,000 receptor (type I receptor) for interleukin‐1 (IL‐1) have been isolated previously by mammalian expression. Here, we report the use of an improved expression cloning method to isolate human and murine cDNA clones encoding a second type (Mr approximately 60,000) of IL‐1 receptor (type II receptor). The mature type II IL‐1 receptor consists of (i) a ligand binding portion comprised of three immunoglobulin‐like domains; (ii) a single transmembrane region; and (iii) a short cytoplasmic domain of 29 amino acids. This last contrasts with the approximately 215 amino acid cytoplasmic domain of the type I receptor, and suggests that the two IL‐1 receptors may interact with different signal transduction pathways. The type II receptor is expressed in a number of different tissues, including both B and T lymphocytes, and can be induced in several cell types by treatment with phorbol ester. Both IL‐1 receptors appear to be well conserved in evolution, and map to the same chromosomal location. Like the type I receptor, the human type II IL‐1 receptor can bind all three forms of IL‐1 (IL‐1 alpha, IL‐1 beta and IL‐1ra). Vaccinia virus contains an open reading frame bearing strong resemblance to the type II IL‐1 receptor.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here